SJL2-1 is a PRMT5 inhibitor with an IC50 value of 1.56 µM. It suppresses the proliferation, migration, and invasion of prostate cancer cells and induces apoptosis while causing cell cycle arrest at the G0/G1 phase. SJL2-1 targets intracellular PRMT5, inhibiting androgen receptor methylation and expression. It is applicable in research on early androgen-sensitive prostate cancer and advanced castration-resistant prostate cancer (CRPC).
